ProQR Therapeutics
PRQR
48 hedge funds and large institutions have $28.6M invested in ProQR Therapeutics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 17 reducing their positions, and 3 closing their positions.
279% more call options, than puts
Call options by funds: $212K | Put options by funds: $56K
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.34% less ownership
Funds ownership: 21.51% → 21.17% (-0.34%)
2% less funds holding
Funds holding: 49 → 48 (-1)
28% less capital invested
Capital invested by funds: $39.8M → $28.6M (-$11.1M)
71% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 17
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
+$1.75M |
| 2 |
PFM
Privium Fund Management
Amsterdam,
Netherlands
|
+$459K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$120K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$43.8K |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$32K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$1.63M |
| 2 |
Millennium Management
New York
|
-$351K |
| 3 |
Squarepoint
New York
|
-$132K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$85.5K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$71.7K |
PRQR Hedge Fund Activity: Q2 2024 in Review
48 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q2 2024, worth a combined $28.6M — down 28% from $39.8M a quarter earlier.
Fund positioning in PRQR was balanced in Q2 2024: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 17 trimmed.
The largest buyer was Ghost Tree Capital, opening a new position worth an estimated $1.75M. The largest seller was EcoR1 Capital, cutting an estimated $1.63M.
- 48 institutional investors held ProQR Therapeutics (PRQR) as of Q2 2024, down from 49 in Q1 2024.
- Funds reported $28.6M of ProQR Therapeutics stock for Q2 2024, down 28% quarter-over-quarter.
- 3 funds opened new ProQR Therapeutics positions in Q2 2024 and 3 closed out, a net change of 0 holders.
- The largest ProQR Therapeutics buyer in Q2 2024 was Ghost Tree Capital, an estimated $1.75M added.
- The largest ProQR Therapeutics seller in Q2 2024 was EcoR1 Capital, an estimated $1.63M sold.
Based on aggregated 13F filings for Q2 2024.